Breaking News

AbbVie Appoints R&D EVP

May 16, 2014

Severino to drive pipeline advancement

Michael Severino, M.D. has been named executive vice president, R&D and chief scientific officer at AbbVie. Dr. Severino will be responsible for leading the R&D, Medical Affairs and Regulatory Affairs organizations. He brings expertise from his career spanning genomics and development within the biotech industry.
 
Dr. Severino most recently served as senior vice president and chief medical officer at Amgen, leading the clinical development strategy across inflammation/immunology, neuroscience, oncology and cardiovascular disease, among other areas. In his ten years with the company, he held numerous roles of increasing responsibility across R&D. Prior to Amgen, Dr. Severino held positions in biologics and genomics research at Merck. 
 
"AbbVie is pleased to welcome Dr. Severino to our new company," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We are fortunate to have a leader of his caliber to steer our efforts to develop treatments for today's toughest health challenges. He will be instrumental in moving our pipeline and strategy forward."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016